X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with NALWA SONS INV - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs NALWA SONS INV - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

NALWA SONS INV 
   Change

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES NALWA SONS INV INDOCO REMEDIES/
NALWA SONS INV
 
P/E (TTM) x 31.7 59.9 53.0% View Chart
P/BV x 3.8 2.3 165.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 INDOCO REMEDIES   NALWA SONS INV
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
NALWA SONS INV
Mar-14
INDOCO REMEDIES/
NALWA SONS INV
5-Yr Chart
Click to enlarge
High Rs360695 51.9%   
Low Rs249452 55.2%   
Sales per share (Unadj.) Rs119.071.5 166.4%  
Earnings per share (Unadj.) Rs8.455.5 15.1%  
Cash flow per share (Unadj.) Rs15.255.5 27.5%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7607.5 11.6%  
Shares outstanding (eoy) m92.155.14 1,792.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.68.0 32.0%   
Avg P/E ratio x36.410.3 352.5%  
P/CF ratio (eoy) x20.010.3 193.6%  
Price / Book Value ratio x4.30.9 456.7%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,0832,947 953.0%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1673 68,350.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968368 2,982.8%  
Other income Rs m400 13,233.3%   
Total revenues Rs m11,007368 2,991.1%   
Gross profit Rs m1,565360 434.1%  
Depreciation Rs m6330-   
Interest Rs m620-   
Profit before tax Rs m909361 252.1%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m13971 196.6%   
Profit after tax Rs m771285 270.4%  
Gross profit margin %14.398.0 14.6%  
Effective tax rate %15.319.6 78.0%   
Net profit margin %7.077.5 9.1%  
BALANCE SHEET DATA
Current assets Rs m5,7252,013 284.3%   
Current liabilities Rs m5,454113 4,846.4%   
Net working cap to sales %2.5517.0 0.5%  
Current ratio x1.017.9 5.9%  
Inventory Days Days6256 110.9%  
Debtors Days Days7231 231.8%  
Net fixed assets Rs m5,3070 5,307,380.0%   
Share capital Rs m18451 358.6%   
"Free" reserves Rs m6,3311,058 598.3%   
Net worth Rs m6,5163,123 208.7%   
Long term debt Rs m1,323297 445.5%   
Total assets Rs m11,9703,848 311.1%  
Interest coverage x15.6NM-  
Debt to equity ratio x0.20.1 213.5%  
Sales to assets ratio x0.90.1 958.8%   
Return on assets %7.07.4 93.9%  
Return on equity %11.89.1 129.6%  
Return on capital %12.410.4 119.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886116 762.8%  
From Investments Rs m-1,706-134 1,269.9%  
From Financial Activity Rs m1,31628 4,632.7%  
Net Cashflow Rs m49710 4,821.4%  

Share Holding

Indian Promoters % 59.2 55.4 106.9%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 12.5 0.6 2,083.3%  
FIIs % 6.0 4.2 142.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 39.6 56.6%  
Shareholders   12,805 23,884 53.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   CHOLAMANDALAM INVEST.  NESCO LIMITED  THOMAS COOK INDIA  GREENPLY IND  MOTILAL OSWAL  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 18, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - TIMKEN INDIA COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS